Background
Diabetic foot ulcers, as shown in the images below, occur as a result of various factors, such as mechanical changes in conformation of the bony architecture of the foot, peripheral neuropathy, and atherosclerotic peripheral arterial disease, all of which occur with higher frequency and intensity in the diabetic population.
Diabetic ulcer of the medial aspect of left first toe before and after appropriate wound care. 
Diabetic ulcer of left fourth toe associated with mild cellulitis. Nonenzymatic glycosylation predisposes ligaments to stiffness. Neuropathy causes loss of protective sensation and loss of coordination of muscle groups in the foot and leg, both of which increase mechanical stresses during ambulation. (See Pathophysiology and Etiology.)
Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes. Diabetes is the leading cause of nontraumatic lower extremity amputations in the United States, with approximately 5% of diabetics developing foot ulcers each year and 1% requiring amputation. (See Epidemiology.)
Physical examination of the extremity having a diabetic ulcer can be divided into examination of the ulcer and the general condition of the extremity, assessment of the possibility of vascular insufficiency,[1] and assessment for the possibility of peripheral neuropathy. (See Clinical Presentation.)
The staging of diabetic foot wounds is based on the depth of soft tissue and osseous involvement.[2, 3, 4] A complete blood cell count should be done, along with assessment of serum glucose, glycohemoglobin, and creatinine levels. (See Workup.)
A vascular surgeon and/or podiatric surgeon should evaluate all patients with diabetic foot ulcers so as to determine the need for debridement, revisional surgery on bony architecture, vascular reconstruction, or soft tissue coverage. (See Treatment and Management.)
Cilostazol is contraindicated in patients with congestive heart failure. See Medication regarding the product's black box warning.
For more information, see Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2.
Pathophysiology
Atherosclerosis and peripheral neuropathy occur with increased frequency in persons with diabetes mellitus (DM).
Diabetes-related atherosclerosis
Overall, people with diabetes mellitus (DM) have a higher incidence of atherosclerosis, thickening of capillary basement membranes, arteriolar hyalinosis, and endothelial proliferation. Calcification and thickening of the arterial media (Mönckeberg sclerosis) are also noted with higher frequency in the diabetic population, although whether these factors have any impact on the circulatory status is unclear.
Diabetic persons, like people who are not diabetic, may develop atherosclerotic disease of large-sized and medium-sized arteries, such as aortoiliac and femoropopliteal atherosclerosis. However, significant atherosclerotic disease of the infrapopliteal segments is particularly common in the diabetic population. Underlying digital artery disease, when compounded by an infected ulcer in close proximity, may result in complete loss of digital collaterals and precipitate gangrene.
The reason for the prevalence of this form of arterial disease in diabetic persons is thought to result from a number of metabolic abnormalities, including high low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) levels, elevated plasma von Willebrand factor, inhibition of prostacyclin synthesis, elevated plasma fibrinogen levels, and increased platelet adhesiveness.
Diabetic peripheral neuropathy
The pathophysiology of diabetic peripheral neuropathy is multifactorial and is thought to result from vascular disease occluding the vasa nervorum; endothelial dysfunction; deficiency of myoinositol-altering myelin synthesis and diminishing sodium-potassium adenine triphosphatase (ATPase) activity; chronic hyperosmolarity, causing edema of nerve trunks; and effects of increased sorbitol and fructose.[5]
The result of loss of sensation in the foot is repetitive stress; unnoticed injuries and fractures; structural foot deformity, such as hammertoes, bunions, metatarsal deformities, or Charcot foot (see the image below), as depicted in the image below; further stress; and eventual tissue breakdown. Unnoticed excessive heat or cold, pressure from a poorly fitting shoe, or damage from a blunt or sharp object inadvertently left in the shoe may cause blistering and ulceration. These factors, combined with poor arterial inflow, confer a high risk of limb loss on the patient with diabetes.
Charcot deformity with mal perforans ulcer of plantar midfoot. To see complete information on Diabetic Neuropathy, please go to the main article by clicking here.
Etiology
The etiologies of diabetic ulceration include neuropathy,[6] arterial disease,[7] pressure,[8] and foot deformity.[9] Diabetic peripheral neuropathy, present in 60% of diabetic persons and 80% of diabetic persons with foot ulcers, confers the greatest risk of foot ulceration; microvascular disease and suboptimal glycemic control contribute.
Charcot foot
Sensory neuropathy involving the feet may lead to unrecognized episodes of trauma due to ill-fitting shoes. Motor neuropathy, causing intrinsic muscle weakness and splaying of the foot on weight bearing, compounds this trauma. The result is a convex foot with a rocker-bottom appearance. Multiple fractures are unnoticed until bone and joint deformities become marked. This is termed a Charcot foot (neuropathic osteoarthropathy) and most commonly is observed in diabetes mellitus, affecting about 2% of diabetic persons.
If a Charcot foot is neglected, ulceration may occur at pressure points, particularly the medial aspect of the navicular bone and the inferior aspect of the cuboid bone. Sinus tracts progress from the ulcerations into the deeper planes of the foot and into the bone. Charcot change can also affect the ankle, causing displacement of the ankle mortise and ulceration, which can lead to the need for amputation.
Epidemiology
According to the National Institute of Diabetes and Digestive and Kidney Diseases, an estimated 16 million Americans are known to have diabetes, and millions more are considered to be at risk for developing the disease. Diabetic foot lesions are responsible for more hospitalizations than any other complication of diabetes. Among patients with diabetes, 15% develop a foot ulcer, and 12-24% of individuals with a foot ulcer require amputation. Indeed, diabetes is the leading cause of nontraumatic lower extremity amputations in the United States. In fact, every year approximately 5% of diabetics develop foot ulcers and 1% require amputation.
Age distribution for diabetic ulcers
Diabetes occurs in 3-6% of Americans. Of these, 10% have type 1 diabetes and are usually diagnosed when they are younger than 40 years. Among Medicare-aged adults, the prevalence of diabetes is about 10% (of these, 90% have type 2 diabetes). Diabetic neuropathy tends to occur about 10 years after the onset of diabetes, and, therefore, diabetic foot deformity and ulceration occur sometime thereafter.
Prevalence of diabetic ulcers by race
The issue of diabetic foot disease is of particular concern in the Latino communities of the Eastern United States, in African Americans,[10] and in Native Americans, who tend to have the highest prevalence of diabetes in the world.
To see complete information on Diabetic Foot, please go to the main article by clicking here.
Prognosis
Mortality in people with diabetes and foot ulcers is often the result of associated large vessel arteriosclerotic disease involving the coronary or renal arteries.
Limb loss is a significant risk in patients with diabetic foot ulcers, particularly if treatment has been delayed.[11] Diabetes is the predominant etiology for nontraumatic lower extremity amputations in the United States. Half of all nontraumatic amputations are a result of diabetic foot complications, and the 5-year risk of needing a contralateral amputation is 50%.[12]
In diabetic people with neuropathy,[13] even if successful management results in healing of the foot ulcer, the recurrence rate is 66% and the amputation rate rises to 12%.
Patient Education
The risk of foot ulceration and limb amputation in people with diabetes is lessened by patient education stressing the importance of routine preventive podiatric care, appropriate shoes, avoidance of cigarette smoking, control of hyperlipidemia, and adequate glycemic control. For excellent patient education resources, visit eMedicine’s Diabetes Center. Also, see eMedicine’s patient education article Diabetic Foot Care.
Gentile AT, Berman SS, Reinke KR, Demas CP, Ihnat DH, Hughes JD, et al. A regional pedal ischemia scoring system for decision analysis in patients with heel ulceration. Am J Surg. Aug 1998;176(2):109-14. [Medline].
Beckert S, Witte M, Wicke C, Königsrainer A, Coerper S. A new wound-based severity score for diabetic foot ulcers: A prospective analysis of 1,000 patients. Diabetes Care. May 2006;29(5):988-92. [Medline].
Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care. Jan 2001;24(1):84-8. [Medline].
Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg. Jul 2000;135(7):773-7. [Medline].
Tomic-Canic M, Brem H. Gene array technology and pathogenesis of chronic wounds. Am J Surg. Jul 2004;188(1A Suppl):67-72. [Medline].
Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. Jul 1 2004;351(1):48-55. [Medline].
Arora S, Pomposelli F, LoGerfo FW, Veves A. Cutaneous microcirculation in the neuropathic diabetic foot improves significantly but not completely after successful lower extremity revascularization. J Vasc Surg. Mar 2002;35(3):501-5. [Medline].
Boulton AJ. Pressure and the diabetic foot: clinical science and offloading techniques. Am J Surg. May 2004;187(5A):17S-24S. [Medline].
Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. May 3 2003;361(9368):1545-51. [Medline].
Marshall MC Jr. Diabetes in African Americans. Postgrad Med J. Dec 2005;81(962):734-40. [Medline]. [Full Text].
Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. Mar 1999;22(3):382-7. [Medline].
Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. Aug 1998;176(2A Suppl):5S-10S. [Medline].
Galkowska H, Olszewski WL, Wojewodzka U, Rosinski G, Karnafel W. Neurogenic factors in the impaired healing of diabetic foot ulcers. J Surg Res. Aug 2006;134(2):252-8. [Medline].
Mayfield JA, Sugarman JR. The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. J Fam Pract. Nov 2000;49(11 Suppl):S17-29. [Medline].
Teodorescu VJ, Chen C, Morrissey N, Faries PL, Marin ML, Hollier LH. Detailed protocol of ischemia and the use of noninvasive vascular laboratory testing in diabetic foot ulcers. Am J Surg. May 2004;187(5A):75S-80S. [Medline].
Christman AL, Selvin E, Margolis DJ, Lazarus GS, Garza LA. Hemoglobin a1c predicts healing rate in diabetic wounds. J Invest Dermatol. Oct 2011;131(10):2121-7. [Medline]. [Full Text].
Dutta P, Bhansali A, Mittal BR, Singh B, Masoodi SR. Instant 99mTc-ciprofloxacin scintigraphy for the diagnosis of osteomyelitis in the diabetic foot. Foot Ankle Int. Sep 2006;27(9):716-22. [Medline].
Edmonds M, Foster A. The use of antibiotics in the diabetic foot. Am J Surg. May 2004;187(5A):25S-28S. [Medline].
O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systematic review of antimicrobial agents used for chronic wounds. Br J Surg. Jan 2001;88(1):4-21. [Medline].
Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg. Jun 2000;135(6):627-34. [Medline].
Beuker BJ, van Deursen RW, Price P, Manning EA, van Baal JG, Harding KG. Plantar pressure in off-loading devices used in diabetic ulcer treatment. Wound Repair Regen. Nov-Dec 2005;13(6):537-42. [Medline].
Hilton JR, Williams DT, Beuker B, Miller DR, Harding KG. Wound dressings in diabetic foot disease. Clin Infect Dis. Aug 1 2004;39 Suppl 2:S100-3. [Medline].
Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. Feb 2001;24(2):290-5. [Medline].
Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg. Feb 2003;90(2):133-46. [Medline].
Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study. Adv Ther. Jul-Aug 2000;17(4):184-9. [Medline].
Platelet-derived growth factor for diabetic ulcers. Med Lett Drugs Ther. Jul 17 1998;40(1031):73-4. [Medline].
Jirkovská A, Boucek P, Wosková V, Bartos V, Skibová J. Identification of patients at risk for diabetic foot: a comparison of standardized noninvasive testing with routine practice at community diabetes clinics. J Diabetes Complications. Mar-Apr 2001;15(2):63-8. [Medline].
Muha J. Local wound care in diabetic foot complications. Aggressive risk management and ulcer treatment to avoid amputation. Postgrad Med. Jul 1999;106(1):97-102. [Medline].
Pinzur MS, Slovenkai MP, Trepman E, Shields NN. Guidelines for diabetic foot care: recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. Foot Ankle Int. Jan 2005;26(1):113-9. [Medline].
Edmonds M. Diabetic foot ulcers: practical treatment recommendations. Drugs. 2006;66(7):913-29. [Medline].
Bello YM, Phillips TJ. Recent advances in wound healing. JAMA. Feb 9 2000;283(6):716-8. [Medline].
Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S, et al. Diabetic foot disorders. A clinical practice guideline. For the American College of Foot and Ankle Surgeons and the American College of Foot and Ankle Orthopedics and Medicine. J Foot Ankle Surg. 2000;Suppl:1-60. [Medline].
Margolis DJ, Kantor J, Santanna J, Strom BL, Berlin JA. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a pooled analysis. Arch Dermatol. Dec 2000;136(12):1531-5. [Medline].
Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJ. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg. Jun 2006;117(7 Suppl):193S-209S; discussion 210S-211S. [Medline].
Evans D, Land L. Topical negative pressure for treating chronic wounds: a systematic review. Br J Plast Surg. Apr 2001;54(3):238-42. [Medline].
Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg. Jun 2006;117(7 Suppl):212S-238S. [Medline].
Wieman TJ, Mercke YK, Cerrito PB, Taber SW. Resection of the metatarsal head for diabetic foot ulcers. Am J Surg. Nov 1998;176(5):436-41. [Medline].
Faries PL, Teodorescu VJ, Morrissey NJ, Hollier LH, Marin ML. The role of surgical revascularization in the management of diabetic foot wounds. Am J Surg. May 2004;187(5A):34S-37S. [Medline].
Marston WA, Davies SW, Armstrong B, Farber MA, Mendes RC, Fulton JJ, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg. Jul 2006;44(1):108-114. [Medline].
Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. Sep 2006;12(9):2407-24. [Medline].
Streit M, Braathen LR. Apligraf--a living human skin equivalent for the treatment of chronic wounds. Int J Artif Organs. Dec 2000;23(12):831-3. [Medline].
Demiri E, Foroglou P, Dionyssiou D, Antoniou A, Kakas P, Pavlidis L, et al. Our experience with the lateral supramalleolar island flap for reconstruction of the distal leg and foot: a review of 20 cases. Scand J Plast Reconstr Surg Hand Surg. 2006;40(2):106-10. [Medline].
Strauss MB. Hyperbaric oxygen as an intervention for managing wound hypoxia: its role and usefulness in diabetic foot wounds. Foot Ankle Int. Jan 2005;26(1):15-8. [Medline].
Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg. Jan 2005;92(1):24-32. [Medline].
[Best Evidence] Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. May 2010;33(5):998-1003. [Medline]. [Full Text].
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. Jan 12 2005;293(2):217-28. [Medline].
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. Sep 30 1993;329(14):977-86. [Medline].
[Best Evidence] Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. Feb 2008;47(2):330-336. [Medline].
[Guideline] Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. Oct 1 2004;39(7):885-910. [Medline].
| Category | Examples | Description | Applications |
| Alginate | AlgiSite Comfeel Curasorb Kaltogel Kaltostat Sorbsan Tegagel | This seaweed extract contains guluronic and mannuronic acids that provide tensile strength and calcium and sodium alginates, which confer an absorptive capacity. Some of these can leave fibers in the wound if they are not thoroughly irrigated. These are secured with secondary coverage. | These are highly absorbent and useful for wounds having copious exudate. Alginate rope is particularly useful to pack exudative wound cavities or sinus tracts. |
| Hydrofiber | Aquacel Aquacel-Ag Versiva | An absorptive textile fiber pad, also available as a ribbon for packing of deep wounds. This material is covered with a secondary dressing. The hydrofiber combines with wound exudate to produce a hydrophilic gel. Aquacel-Ag contains 1.2% ionic silver that has strong antimicrobial properties against many organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. | These are absorbent dressings used for exudative wounds. |
| Debriding agents | Hypergel (hypertonic saline gel) Santyl (collagenase) Accuzyme (papain urea) | Various products provide some degree of chemical or enzymatic debridement. | These are useful for necrotic wounds as an adjunct to surgical debridement. |
| Foam | LYOfoam Spyrosorb Allevyn | Polyurethane foam has some absorptive capacity. | These are useful for cleaning granulating wounds having minimal exudate. |
| Hydrocolloid | Aquacel CombiDERM Comfeel Duoderm CGF Extra Thin Granuflex Tegasorb | These are made of microgranular suspension of natural or synthetic polymers, such as gelatin or pectin, in an adhesive matrix. The granules change from a semihydrated state to a gel as the wound exudate is absorbed. | They are useful for dry necrotic wounds, wounds having minimal exudate, and clean granulating wounds. |
| Hydrogel | Aquasorb Duoderm IntraSite Gel Granugel Normlgel Nu-Gel Purilon Gel (KY jelly) | These are water-based or glycerin-based semipermeable hydrophilic polymers; cooling properties may decrease wound pain. These gels can lose or absorb water depending upon the state of hydration of the wound. They are secured with secondary covering. | These are useful for dry, sloughy, necrotic wounds (eschar). |
| Low-adherence dressing | Mepore Skintact Release | These are various materials designed to remove easily without damaging underlying skin. | These are useful for acute minor wounds, such as skin tears, or as a final dressing for chronic wounds that have nearly healed. |
| Transparent film | OpSite Skintact Release Tegaderm Bioclusive | These are highly conformable acrylic adhesive film having no absorptive capacity and little hydrating ability, and they may be vapor permeable or perforated. | These are useful for clean dry wounds having minimal exudate, and they also are used to secure an underlying absorptive material. They are used for protection of high-friction areas and areas that are difficult to bandage such as heels (also used to secure IV catheters). |
Print
